PL3352752T3 - Wykrywanie i leczenie niedoboru hormonu wzrostu - Google Patents

Wykrywanie i leczenie niedoboru hormonu wzrostu

Info

Publication number
PL3352752T3
PL3352752T3 PL16849470T PL16849470T PL3352752T3 PL 3352752 T3 PL3352752 T3 PL 3352752T3 PL 16849470 T PL16849470 T PL 16849470T PL 16849470 T PL16849470 T PL 16849470T PL 3352752 T3 PL3352752 T3 PL 3352752T3
Authority
PL
Poland
Prior art keywords
detection
treatment
growth hormone
hormone deficiency
deficiency
Prior art date
Application number
PL16849470T
Other languages
English (en)
Polish (pl)
Inventor
Michael THORNER
Original Assignee
Lumos Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lumos Pharma Inc. filed Critical Lumos Pharma Inc.
Publication of PL3352752T3 publication Critical patent/PL3352752T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/61Growth hormones [GH] (Somatotropin)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/65Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PL16849470T 2015-09-21 2016-09-21 Wykrywanie i leczenie niedoboru hormonu wzrostu PL3352752T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562221191P 2015-09-21 2015-09-21
US201662289221P 2016-01-30 2016-01-30
EP16849470.6A EP3352752B1 (en) 2015-09-21 2016-09-21 Detecting and treating growth hormone deficiency
PCT/US2016/052800 WO2017053373A1 (en) 2015-09-21 2016-09-21 Detecting and treating growth hormone deficiency

Publications (1)

Publication Number Publication Date
PL3352752T3 true PL3352752T3 (pl) 2022-04-19

Family

ID=58276481

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16849470T PL3352752T3 (pl) 2015-09-21 2016-09-21 Wykrywanie i leczenie niedoboru hormonu wzrostu
PL21192867.6T PL3939590T3 (pl) 2015-09-21 2016-09-21 Wykrywanie i leczenie niedoboru hormonu wzrostu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL21192867.6T PL3939590T3 (pl) 2015-09-21 2016-09-21 Wykrywanie i leczenie niedoboru hormonu wzrostu

Country Status (23)

Country Link
US (5) US9763919B2 (https=)
EP (3) EP3352752B1 (https=)
JP (5) JP6816149B2 (https=)
KR (4) KR20250102122A (https=)
CN (2) CN116459250A (https=)
AU (5) AU2016328969B2 (https=)
CA (1) CA2998523C (https=)
CY (1) CY1125183T1 (https=)
DK (2) DK3939590T3 (https=)
ES (2) ES2967259T3 (https=)
FI (1) FI3939590T3 (https=)
HR (1) HRP20220317T1 (https=)
HU (2) HUE057831T2 (https=)
IL (1) IL258224B (https=)
LT (1) LT3352752T (https=)
PL (2) PL3352752T3 (https=)
PT (2) PT3939590T (https=)
RS (1) RS62988B1 (https=)
SG (2) SG10202010598SA (https=)
SI (1) SI3352752T1 (https=)
SM (1) SMT202200167T1 (https=)
UA (1) UA123865C2 (https=)
WO (1) WO2017053373A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11234969B2 (en) * 2016-01-30 2022-02-01 Lumos Pharma, Inc. Detecting and treating growth hormone deficiency
HUE057831T2 (hu) * 2015-09-21 2022-06-28 Lumos Pharma Inc Növekedési hormon hiányának felismerése és kezelése
US10288629B1 (en) * 2017-12-19 2019-05-14 Aeterna Zentaris, Inc. Method of assessing growth hormone deficiency in humans by a macimorelin containing composition
WO2020041322A1 (en) 2018-08-20 2020-02-27 Berkowitz Barry A Novel cannabinoids and cannabinoid acids and their derivatives
US11644474B2 (en) * 2020-07-22 2023-05-09 Æterna Zentaris Gmbh Use of macimorelin in assessing growth hormone deficiency in children
KR20250107210A (ko) * 2022-11-03 2025-07-11 루모스 파마, 인크. 이부타모렌의 압축형 경구 제형

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000759A1 (en) * 1992-06-29 1994-01-06 University Of South Florida Diagnostic procedure for evaluating short stature etiology
US5756507A (en) * 1995-12-14 1998-05-26 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
ATE344667T1 (de) 1997-08-22 2006-11-15 Kaken Pharma Co Ltd Amide zur förderung der ausschüttung von wachstumshormonen
ATE446758T1 (de) 2000-05-31 2009-11-15 Pfizer Prod Inc Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
AR029941A1 (es) 2000-06-13 2003-07-23 Zentaris Gmbh Compuestos utiles para elevar el nivel plasmatico de la hormona del crecimiento y las composiciones farmaceuticas que las contienen
BRPI0414175A (pt) * 2003-09-19 2006-10-31 Pfizer Health Ab método melhorado de tratamento de distúrbios do crescimento
NZ547752A (en) 2003-11-12 2009-12-24 Phenomix Corp Heterocyclic boronic acid compounds for inhibiting dipeptidyl peptidase-IV
GB0603295D0 (en) 2006-02-18 2006-03-29 Ardana Bioscience Ltd Methods and kits
WO2013163455A2 (en) * 2012-04-25 2013-10-31 The Regents Of The University Of California A drug screening platform for rett syndrome
US11234969B2 (en) * 2016-01-30 2022-02-01 Lumos Pharma, Inc. Detecting and treating growth hormone deficiency
HUE057831T2 (hu) * 2015-09-21 2022-06-28 Lumos Pharma Inc Növekedési hormon hiányának felismerése és kezelése

Also Published As

Publication number Publication date
KR102560838B1 (ko) 2023-07-27
JP7724831B2 (ja) 2025-08-18
PT3939590T (pt) 2024-01-23
JP7104768B2 (ja) 2022-07-21
AU2021254600A1 (en) 2021-11-18
KR20220047407A (ko) 2022-04-15
IL258224A (en) 2018-05-31
AU2020233715A1 (en) 2020-10-22
JP6816149B2 (ja) 2021-01-20
KR20230116961A (ko) 2023-08-04
US20190015394A1 (en) 2019-01-17
JP2024026112A (ja) 2024-02-28
EP3939590A1 (en) 2022-01-19
PT3352752T (pt) 2022-03-09
US10105352B2 (en) 2018-10-23
DK3939590T3 (da) 2023-12-18
NZ741142A (en) 2025-05-02
AU2024201658A1 (en) 2024-04-04
FI3939590T3 (fi) 2023-12-14
SI3352752T1 (sl) 2022-05-31
AU2024201658C1 (en) 2026-02-12
AU2025237934A1 (en) 2025-10-16
US20180071266A1 (en) 2018-03-15
KR102385669B1 (ko) 2022-04-13
HUE065224T2 (hu) 2024-05-28
JP7389862B2 (ja) 2023-11-30
IL258224B (en) 2021-10-31
HUE057831T2 (hu) 2022-06-28
CN116459250A (zh) 2023-07-21
US10898472B2 (en) 2021-01-26
JP2021063096A (ja) 2021-04-22
EP3352752A1 (en) 2018-08-01
UA123865C2 (uk) 2021-06-16
EP4296679A3 (en) 2024-04-10
AU2020233715B2 (en) 2021-09-30
CA2998523C (en) 2023-08-01
US20220142989A1 (en) 2022-05-12
US20250213536A1 (en) 2025-07-03
HRP20220317T1 (hr) 2022-05-13
PL3939590T3 (pl) 2024-03-25
HK1263178A1 (zh) 2020-01-31
LT3352752T (lt) 2022-04-11
ES2908423T3 (es) 2022-04-29
EP3939590B1 (en) 2023-11-29
KR20250102122A (ko) 2025-07-04
KR20180082428A (ko) 2018-07-18
US20170079961A1 (en) 2017-03-23
RS62988B1 (sr) 2022-03-31
AU2016328969A1 (en) 2018-04-26
CN108348501A (zh) 2018-07-31
EP3352752A4 (en) 2019-06-12
SG10201902424TA (en) 2019-04-29
CY1125183T1 (el) 2023-06-09
EP3352752B1 (en) 2021-12-22
SMT202200167T1 (it) 2022-05-12
DK3352752T3 (da) 2022-02-28
SG10202010598SA (en) 2020-11-27
JP2022163012A (ja) 2022-10-25
CA2998523A1 (en) 2017-03-30
JP2018529766A (ja) 2018-10-11
WO2017053373A1 (en) 2017-03-30
AU2021254600B2 (en) 2024-02-15
AU2016328969B2 (en) 2020-10-08
ES2967259T3 (es) 2024-04-29
US9763919B2 (en) 2017-09-19
EP4296679A2 (en) 2023-12-27
US12539293B2 (en) 2026-02-03
AU2024201658B2 (en) 2025-10-30
JP2025170274A (ja) 2025-11-18

Similar Documents

Publication Publication Date Title
IL257105A (en) Modified cells and methods of therapy
IL282048A (en) Oxysterols and methods of use thereof
IL255269A (en) Compositions of obeticholic acid and methods of use
PT3694529T (pt) Proteínas triespecíficas e métodos de utilização
IL253162A0 (en) Compositions and methods for treatment and detection of cancers
PL3402888T3 (pl) Środki i sposoby leczenia hbv
PL3353210T3 (pl) Przeciwciała anty-TIGIT i sposoby stosowania
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
EP4212536C0 (en) BENZOXAZEPINE OXAZOLIDINONE COMPOUNDS AND METHODS OF USE
PL3828194T3 (pl) Oksysterole i sposoby ich stosowania
EP3681479A4 (en) METHOD OF ADMINISTRATION AND TREATMENT
IL252602B (en) Oral care compositions and methods of use
PL3362084T3 (pl) Urządzenia do podawania dojelitowego i powiązane sposoby zastosowania
LT3277842T (lt) Vėžio pacientų gydymo būdai farneziltransferazės inhibitoriais
HUE056287T2 (hu) Pancreatitis kezelése
PL3371206T3 (pl) Sposoby wytwarzania postaci fukozylowanej i niefukozylowanej białka
IL258259B (en) Adjunctive therapy with 25-hydroxyvitamin d and articles therefor
LT3341027T (lt) Transfekcijos kompleksai ir jų panaudojimo būdai
EP3334429C0 (en) HYPERPHENYLALANINEMIA AND TREATMENTS THEREFOR
IL251759B (en) Compositions and methods for treating insomnia
PL3189074T3 (pl) Kompozycje oraz sposoby leczenia i zapobiegania zapaleniom
IL261740A (en) Compositions and methods for treatment of type vii collagen deficiencies
PL3397967T3 (pl) Kompozycje i sposoby do wykrywania i leczenia raka przełyku
PL3352752T3 (pl) Wykrywanie i leczenie niedoboru hormonu wzrostu
IL254825A0 (en) Methods of treatment with taselisib